Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013

Chemotherapy

Volumn 59, Issue 5, 2014, Pages 373-378

  Takemoto, Yuji ^a   Asai, Teizaburo ^d   Ikezoe, Itsuo ^b   Yano, Takako ^e   Ichikawa, Masahiro ^c   Miyagawa, Shogo ^f   Matsumoto, Jun ^g  

^a Kamijyo Clinic   (Japan)

^b Ikezoe Clinic   (Japan)

^c Ichikawa Pediatric Clinic   (Japan)

^d Asai Pediatric Clinic   (Japan)

^e Mori Yano Clinic   (Japan)

^f Miyagawa Clinic   (Japan)

^g Matsumoto Clinic   (Japan)

Author keywords

Fever; Influenza virus; Neuraminidase inhibitors

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; SIALIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEASONAL INFLUENZA; VERY ELDERLY; WINTER; YOUNG ADULT; ABSENCE OF SIDE EFFECTS; ARTHRALGIA; CONTROLLED STUDY; COUGHING; INFLUENZA; INFLUENZA VIRUS; MALAISE; REVIEW; RHINORRHEA; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; INFLUENZA, HUMAN; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYCLOPENTANES; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFANT; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; OUTPATIENTS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT; ZANAMIVIR;

EID: 84899774389     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000362436     Document Type: Article

References (22)

1. Chang M, Southard C, Sullivan M: Learning from the 2009 H1N1 influenza pandemic. Risk Management Solutions Special Report, 2010.
2. Lenzi L, Mello ÂM, Silva LR, Grochocki MH, Pontarolo R: Pandemic influenza A(H1N1) 2009: risk factors for hospitalization. J Bras Pneumol 2012; 38: 57-65.
3. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva, World Health Organization (revised February 2010).
4. Kohno S, Kida H, Mizuguchi M, Shimada J; the S-021812 Clinical Study Group: Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54: 4568-4574.
5. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H: Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1) pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother 2012; 18: 858-864.
6. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K: Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47: 339-345.
7. Sugaya N, Ohashi Y: Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54: 2575-2582.
8. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T: Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012; 56: 369-377.
9. Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, Hirotsu N, Nishimura M, Iwaki N, Kashiwagi S: Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. J Infect Chemother 2011; 17: 375-381.
10. Toovey S, Dutkowski R, Smith P, Smith JR: Oseltamivir effectiveness in seasonal influenza patients taking symptomatic therapy: retrospective analysis of RCT data: Int J Clin Pharmacol Ther 2013; 51: 932-941.
11. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J; S-021812 Clinical Study Group: Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55: 5267-5276.
12. http://www.nih.go.jp/niid/images/iasr/rapid/ inf/2013-20w/sinin1-130516. gif.
13. http://www.nih.go.jp/niid/images/flu/resistance/ 20131011/dr12- 13j20131011-1.gif.
14. Centers for Disease Control and Prevention: Interim adjusted estimates of seasonal influenza vaccine effectiveness-United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 119-123.
15. http://www.nih.go.jp/niid/ja/flu-m/2066-idsc/related/584-atpcs002.html.
16. Valenciano M, Kissling E: I-MOVE Case-Control Study Team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill 2013; 18: 3.
17. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M: Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012; 156: 500-511.
18. Chu H, Lofgren ET, Halloran ME, Kuan PF, Hudgens M, Cole SR: Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis. Influenza Other Respir Viruses 2012; 6: 80-86.
19. Laver WG, Bischofberger N, Webster RG: Disarming flu viruses. Sci Am 1999; 280: 79-87.
20. Romanutti C, Bruttomesso AC, Castilla V, Galagovsky LR, Wachsman MB: Anti-adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives. Chemotherapy 2010; 56: 158-165.
21. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S: Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr 2012; 2012: 834181.
22. Okabe N: Epidemiological situation on pandemic influenza H1N1 2009 in the world and in Japan. JMA J 2011; 54: 277-283.